Current in-house programmes are focussed on autoimmune, anti-inflammatory and anti-angiogenesis conditions where current first-line small molecule and biologic therapies are failing to deliver the required disease outcomes for all patients.

Using the inherent qualities of their small size, stable nature and unique neutralisation potencies, Elasmogen is developing site-specific soloMERs that can deliver rapid alleviation of disease, minimise systemic exposure and side-effects and offer the promise of self-administered, longer-term treatments.